Novo Nordisk Ties Its Future to Oral GLP-1s and Cardiovascular Data as Semaglutid Cliff Nears

Novo Nordisk licenses Hengrui's oral GLP-1/GIP candidate for up to USD 2.6 billion and releases data backing Semaglutide against Tirzepatide.

Novo Nordisk is assembling a broader metabolic-medicine portfolio on two fronts at once — buying into early-stage science from abroad while rolling out real-world evidence meant to defend its existing franchise. The Danish drugmaker's dual strategy landed against a backdrop of persistent share-price weakness, with the stock changing hands at EUR 33.38 on the day of the Hengrui announcement, a decline of 1.2 percent.

The licensing move, disclosed yesterday, hands Novo Nordisk worldwide rights to HRS-1596 from China's Jiangsu Hengrui Pharmaceuticals, excluding mainland China, Hong Kong, Macau and Taiwan. The candidate is a dual GLP-1/GIP receptor agonist formulated as a once-weekly tablet and aimed at obesity, type-2 diabetes and other metabolic disorders. It has already cleared Chinese regulators to enter Phase I trials for weight management and type-2 diabetes.

Financial terms carry a USD 300 million upfront payment and up to USD 2.3 billion in milestone payments, putting the deal's potential value at USD 2.6 billion. On top of development, regulatory and commercial milestones, the pact includes royalties on future net sales across the licensed territory. The transaction faces US antitrust review under the Hart-Scott-Rodino Act and customary closing conditions, with completion targeted for the fourth quarter of 2026.

A crowded race toward pills

Convenience is becoming a battleground in obesity care, where most established therapies still require weekly injections. Analysts peg the annual market for obesity and diabetes treatments at roughly USD 100 billion over the coming decade. Novo Nordisk's management has been shopping externally to widen its technological base: last Friday it secured rights to the PharmaShell platform technology from Sweden's Nanexa for up to five development programs spanning obesity, type-2 diabetes and cardiometabolic disease.

The Hengrui deal drew little fresh momentum from traders. Market watchers pointed to the project's early stage, noting that human efficacy and tolerability data are still pending. Evan Seigerman of BMO Capital kept a "Market Perform" rating on Novo Nordisk with a USD 47 price target, arguing that a weekly oral agent could offer long-term differentiation but does nothing to shift the competitive landscape in the near term. Markus Manns, a portfolio manager at Union Investment, pressed for faster progress, saying the pipeline above all needs assets that are further along in development.

Cardiovascular edge in the spotlight

Alongside the licensing push, Novo Nordisk unveiled practice-based data intended to strengthen Semaglutid against its closest rival. A retrospective study of 636,525 adults with type-2 diabetes found that raising the Semaglutid dose cut the risk of major cardiovascular events by 6 percent compared with switching patients to Eli Lilly's Tirzepatid, the company reported yesterday.

The findings slot into a run of scientific wins. On September 21, Novo Nordisk released initial results from the Phase 3 REIMAGINE 5 trial, in which the CagriSema combination at a 1.0 mg / 1.0 mg dose produced an estimated average weight loss of 12.4 percent, versus 9.1 percent for subjects on 5 mg Tirzepatid. Those numbers are meant to show that the company's next-generation candidates remain competitive in the race for maximum efficacy, as clinical superiority in complications such as vascular damage and heart attacks increasingly drives decisions by physicians and payers — not just raw sales figures.

Analysts stay cautious after the slide

Operational moves have yet to translate into market relief. The stock is down 23 percent since the start of the year, and institutional observers remain guarded despite the recent trial data and acquisitions. Deutsche Bank trimmed its price target on September 22 to DKK 245 from DKK 265, keeping a sell recommendation. Bank of America Securities followed on Friday with a "Hold" rating.

For Novo Nordisk, the clock is ticking on securing its long-term position: patent protection for its key Semaglutid medicine is expected to lapse in the US and Europe in the early 2030s. Whether the reported data advantages prove sufficient to ease pressure in the cardiometabolic market is the question investors now face.